| Care provision and prescribing practices of physicians treating children and adolescents with ADHD A Patel, R Medhekar, M Ochoa-Perez, RR Aparasu, W Chan, JT Sherer, ... Psychiatric Services 68 (7), 681-688, 2017 | 35 | 2017 |
| The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis T Do, R Medhekar, R Bhat, H Chen, P Niravath, MV Trivedi Breast cancer research and treatment 153, 591-597, 2015 | 27 | 2015 |
| Risk factors of psychotropic polypharmacy in the treatment of children and adolescents with psychiatric disorders R Medhekar, R Aparasu, V Bhatara, M Johnson, J Alonzo, ... Research in Social and Administrative Pharmacy 15 (4), 395-403, 2019 | 21 | 2019 |
| A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting RM Rifkin, R Medhekar, ES Amirian, KM Aguilar, T Wilson, M Boyd, ... Therapeutic Advances in Hematology 10, 2040620718816699, 2019 | 19 | 2019 |
| Effect of psychopharmacotherapy on body mass index among children and adolescents with bipolar disorders A Patel, W Chan, RR Aparasu, M Ochoa-Perez, JT Sherer, R Medhekar, ... Journal of Child and Adolescent Psychopharmacology 27 (4), 349-358, 2017 | 18 | 2017 |
| Sharing of ADHD information between parents and teachers using an EHR-linked application JJ Michel, S Mayne, RW Grundmeier, JP Guevara, NJ Blum, TJ Power, ... Applied Clinical Informatics 9 (04), 892-904, 2018 | 13 | 2018 |
| Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and … R Medhekar, T Ran, AZ Fu, S Patel, S Kaila BMC cancer 22 (1), 901, 2022 | 12 | 2022 |
| Daratumumab improves depth of response and progression-free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma AJ Jakubowiak, S Kumar, R Medhekar, H Pei, P Lefebvre, S Kaila, J He, ... The oncologist 27 (7), e589-e596, 2022 | 12 | 2022 |
| Floating and bioadhesive delivery system of metoprolol succinate: Formulation, development and in vitro evaluation M Rathi, R Medhekar, A Pawar, C Yewale, V Gudsoorkar Asian Journal of Pharmaceutics (AJP) 6 (3), 2012 | 9 | 2012 |
| Physician care coordination and the use of psychotropic polypharmacy in the management of pediatric mental disorders R Medhekar, K Fujimoto, RR Aparasu, VS Bhatara, ML Johnson, ... Journal of Managed Care & Specialty Pharmacy 25 (1), 29-38, 2019 | 8 | 2019 |
| Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma D Siegel, K Weisel, A Zahlten-Kumeli, R Medhekar, B Ding, X Leleu Leukemia & Lymphoma 62 (12), 3002-3010, 2021 | 7 | 2021 |
| Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients N Raje, R Medhekar, S Panjabi, DM Hines, X Wang, K Iskander, ... Journal of Oncology Pharmacy Practice 28 (5), 1130-1139, 2022 | 4 | 2022 |
| Carfilzomib 56mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus Daratumumab in combination with 8 cycles of Bortezomib and Dexamethasone (DVd … K Weisel, A Nooka, E Terpos, A Spencer, H Goldschmidt, I Majer, ... Blood 136, 8-9, 2020 | 4 | 2020 |
| Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States SK Kumar, I Majer, S Panjabi, R Medhekar, M Campioni, MA Dimopoulos Expert Review of Hematology 13 (6), 687-696, 2020 | 4 | 2020 |
| Survey of patients and physicians on shared decision-making in treatment selection in relapsed/refractory multiple myeloma CL Bylund, S Eggly, TW LeBlanc, S Kurtin, M Gandee, R Medhekar, A Fu, ... Translational Behavioral Medicine 13 (4), 255-267, 2023 | 3 | 2023 |
| Could patients with multiple myeloma (MM) derive additional benefit from their treatments? Real-world evidence for carfilzomib dosing intensity on survival and treatment … R Medhekar, D Hines, S Panjabi, T Welliver, X Wang, RL Wade Blood 132, 836, 2018 | 3 | 2018 |
| Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients T Ran, R Medhekar, AZ Fu, S Patel, S Kaila Future Oncology 18 (36), 3983-3991, 2022 | 2 | 2022 |
| Evolving unmet need in patients refractory to lenalidomide: Overview of the clinical trials in relapsed/refractory multiple myeloma MV Mateos, R Medhekar, I Majer, M Turgut Blood 136, 22-23, 2020 | 2 | 2020 |
| Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed … LN Gordan, CR Tan, R Vescio, JC Ye, C Schinke, R Medhekar, AZ Fu, ... Clinical Lymphoma Myeloma and Leukemia 24 (1), 55-63, 2024 | 1 | 2024 |
| Systematic literature review and meta-analysis of comparative clinical evidence investigating daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide … L Gordan, R Medhekar, AZ Fu, AO Ramirez, N Bonar, BN Nguyen, ... Blood 142, 1963, 2023 | 1 | 2023 |
